semaglutide's anti-inflammatory effects may help reset these pathways independently of weight loss alone
There were statistically significant differences among categories of weight regain at week 88 for the changes from week 0 to week 36 in weight, BMI, and WC
Variants in GLP1R (the GLP-1 receptor itself), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide
On the other hand, GLP-1, which comes from a different part of the gut, not only helps with insulin but also has a broader range of benefits, including reducing appetite, slowing down how quickly your stomach empties after eating, and even having protective effects on the brain